Game Changer: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Publication date: Available online 31 October 2018

Source: Journal of the American Academy of Dermatology

Author(s): Eden Lake

https://ift.tt/2qlzTaj